Agios Pharmaceuticals (AGIO) Cash from Financing Activities (2012 - 2026)

Agios Pharmaceuticals (AGIO) has 15 years of Cash from Financing Activities data on file, last reported at $3.1 million in Q2 2026.

• Quarterly Cash from Financing Activities rose 4744.62% year-over-year to $3.1 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $12.2 million (up 33.35% YoY) and the FY2025 annual result came in at $8.7 million, down 39.93% from the prior year.
• Cash from Financing Activities rose to $3.1 million in Q2 2026, from $2.1 million in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $5.9 million in Q1 2024 to a low of -$67000.0 in Q2 2022.
• A 5-year average of $2.0 million and a median of $1.8 million in 2023 frame the typical range for Cash from Financing Activities.
• Annual changes were most pronounced in 2025 — Cash from Financing Activities plunged 94.09% — and 2026, when it jumped 4744.62%.
• Tracing AGIO's Cash from Financing Activities over 5 years: stood at $22000.0 in 2022, then surged by 3750.0% to $847000.0 in 2023, then jumped by 471.66% to $4.8 million in 2024, then sank by 47.19% to $2.6 million in 2025, then climbed by 23.15% to $3.1 million in 2026.
• The last three Cash from Financing Activities figures came in at $3.1 million (Q2 2026), $2.1 million (Q1 2026), and $2.6 million (Q4 2025), per Business Quant data.